Biacore 3000 shared instrument

描述（由申请人提供）：Biacore 3000系统利用表面等离子体共振技术为生物分子结合的无标签研究提供自动化和敏感的技术。样品范围从小分子到粗提取物，脂质囊泡，病毒，细菌和真核细胞都可以研究。SPR技术的一般优点包括快速、敏感、通用、材料用量少、无标签。目前唯一可用的仪器是bialite升级，即使与常规BiacoreX相比，该仪器在自动化、温度范围和灵敏度方面也存在不足。用户的应用程序将检查蛋白质-蛋白质，蛋白质-核酸和蛋白质药物相互作用。该应用程序的核心小组通过使用改进的BiacoreX （bialite升级）仪器，具有使用该技术的经验，包括出版物。BiacoreX的局限性包括缺乏自动样品处理、灵敏度降低、温度使用范围有限以及传感器芯片上仅使用一半的液流池。此外，the-3000专为单个样品表征而设计，其中动力学分析中的最高分辨率至关重要，范围从4 RU到70000。升级到3000将克服所有这些限制，在实验设计和可能的分析类型方面具有更大的灵活性。该仪器将被放置在由该仪器的核心用户之一Greg Buck博士管理的核酸研究核心设施中。已经确定了一个专门的操作员来运行样本并协助用户进行数据分析。这种设置将允许核心用户以及整个研究界更大程度地访问该仪器。仪器的运行和维护将通过用户费用以及癌症中心和生命科学中心的大学支持来支持。

DESCRIPTION (provided by applicant): The Biacore 3000 system utilizes surface plasmon resonance technology to provide automated and sensitive technology for for label free studies of biomolecular binding. Samples ranging from small molecules to crude extracts, lipid vesicles, viruses, bacteria and eucaryotic cells can be studied. General advantages of SPR technology include being rapid, sensitive, versatile, small amount of material used, and is label-free. The only currently available instrument is a bialite upgrade that is deficient in automation, temperature range and sensitivity, even when compared to the regular BiacoreX. The users have applications which will examine protein-protein, protein-nucleic acid and protein drug interactions. The core group in this application has experience, including publications, using this technology via the use of the modified BiacoreX (bialite upgrade) instrument. The limitations of the BiacoreX include the lack of automatic sample handling, decreased sensitivity, limited temperature use range and use of only one-half of the flow cells on the sensor chip. In addition, the-3000 is designed for individual sample characterization where the highest resolution in kinetic analysis is essential and the range goes from as little as 4 RU to 70000. Upgrading to the 3000 will overcome all of these limitations, allowing much greater flexibility in experiment design and types of analyses that are possible. The instrument will be placed in the nucleic acids research core facility, run by Dr. Greg Buck, one of the core users of the instrument. A dedicated operator has been identified to run samples and assist users with data analysis. This set-up will allow much greater access to the instrument for both the core users as well as the research community as a whole. Support for the instrument operation and maintenance will be through user fees as well as university support from the cancer center and life sciences center.